TY - JOUR
T1 - Targeting the adaptive immune system
T2 - New strategies in the treatment of atherosclerosis
AU - Zarzycka, Barbara
AU - Nicolaes, Gerry A.F.
AU - Lutgens, Esther
N1 - Funding Information:
G Nicolaes was supported by a medium investment grant, the Cardiovascular Research Institute Maastricht, the Transnational University Lim-burg, and Cyttron II FES0908. The authors acknowledge the support from the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences for the GENIUS project “ Generating the best evidence-based pharmaceutical targets for atherosclerosis” (CVON2011-19).E Lutgens wassupported by the Netherlands Organization for Scientific Research [vici grant], and the Deutsche For-schungsgemeinschaft [SFB914, SFB 1054 and SFB1123. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© Informa UK, Ltd.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Atherosclerosis is a lipid-driven chronic inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatments that target the inflammatory nature of atherosclerosis are still under development. Discovery of novel targets involved in the inflammation of the arterial wall creates opportunities to design new therapeutics that successfully modulate atherosclerosis. Here, we review drug targets that have proven to play pivotal roles in the adaptive immune system in atherosclerosis, and we discuss their potential as novel therapeutics.
AB - Atherosclerosis is a lipid-driven chronic inflammatory disease of the arterial wall. Current treatment of atherosclerosis is focused on limiting its risk factors, such as hyperlipidemia or hypertension. However, treatments that target the inflammatory nature of atherosclerosis are still under development. Discovery of novel targets involved in the inflammation of the arterial wall creates opportunities to design new therapeutics that successfully modulate atherosclerosis. Here, we review drug targets that have proven to play pivotal roles in the adaptive immune system in atherosclerosis, and we discuss their potential as novel therapeutics.
KW - adaptive immune system
KW - atherosclerosis
KW - drug discovery
KW - target identification
UR - http://www.scopus.com/inward/record.url?scp=84928616803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928616803&partnerID=8YFLogxK
U2 - 10.1586/17512433.2015.1025052
DO - 10.1586/17512433.2015.1025052
M3 - Review article
C2 - 25843158
AN - SCOPUS:84928616803
VL - 8
SP - 297
EP - 313
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
SN - 1751-2433
IS - 3
ER -